Everolimus, CB-839 Combination Active in Advanced RCC

The combination of CB-839, a selective inhibitor of glutaminase, and everolimus seems to have disease activity in patients with advanced renal cell carcinoma.

Source: CancerNetwork - December 2, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers Kidney Cancer News Renal Cell Carcinoma Source Type: news